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Abstract: Background: Dynamic epigenetic alterations accompanying CD4+ 
T helper cell differentiation have been implicated in multiple autoimmune 
diseases. The bromodomain and extra-terminal (BET) proteins are epigenetic 
regulators that recognize and bind to acetylated histones in chromatin and are 
targets for pharmacological inhibition. In this study we tested a new BET 
inhibitor under clinical development, OTX015, to interrogate its effects on key 
CD4+ T cell subsets associated with autoimmunity. 
Methods: Naïve and memory murine and human CD4+ T cells were isolated 
and differentiated into populations characterized by the expression of interferon 
(IFN)- and interleukin (IL)-17 Cultured cells were then exposed to varying 
concentrations of OTX015 in vitro, and its impact on cytokine expression was 
quantified by flow cytometry. In parallel, the expression of the transcription 
factors TBX21 and RORC was quantified by PCR. A previously studied BET 
inhibitor JQ1 was used as a pharmacological control. 
Results: OTX015 suppressed both murine and human CD4+ T cell proliferation. 
Its impact on cytokine expression varied in murine and human naïve and 
memory subsets. Higher concentrations of OTX015 also had a greater impact 
on the viability of murine versus human cells. IL-17 and IFN- expression was 
not altered in murine memory CD4+ T cells, whereas in human memory CD4+ 
T cells, OTX015 inhibited IL-17, but not IFN-. Across all human T cell subsets 
OTX015 suppressed IL-17 more effectively than IFN-.  
Conclusion: Our studies demonstrate that OTX015 has anti-inflammatory 
effects by suppressing murine and human CD4+ T cell proliferation and subset-
dependent proinflammatory cytokine expression, including the selective 
suppression of IL-17 in human memory CD4+ T cells. 
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Aberrant activation and expansion of CD4+ T helper (Th) cells and their 
secreted effector cytokines underlie the pathogenesis of many autoimmune 
diseases. The mechanism by which CD4+ T cells are abnormally activated and 
proliferate in these disorders remains elusive, but epigenetic dysregulation has 
been implicated in a range of conditions, including systemic lupus 
erythematosus rheumatoid arthritis, uveitis, systemic sclerosis and type I 
diabetes [1-4]. Epigenetic modulation empowers the differential expression of 
lineage-specific signature genes in T cells to dictate T cell fate and function and 
regulate the immune system [5]. Consequently, therapeutics targeting 
epigenetic proteins are being developed to fine-tune the immune response with 
a view to clinical application in the treatment of autoimmune disorders [6,7]. 
Chromatin regulators are a class of proteins that affect gene expression by 
influencing the accessibility of transcription factors and co-factors to 
chromosomal DNA. Typically, chromatin regulators include writer proteins that 
add post-translational modifications (PTMs) to histones, reader proteins that 
recognize PTMs, and eraser proteins that remove PTMs from histones [8]. 
Bromodomain extra-terminal (BET) family proteins belong to chromatin readers. 
They are comprised of four members: BRD2, BRD3, BRD4, and BRDT [9]. BET 
proteins recognize acetylated lysine residues through their bromodomains, 
recruit transcriptional coactivators, and promote pro-inflammatory and 
oncogenic gene expression [9,11], and it has been reported that BET inhibition 
promotes cell differentiation, inhibits proliferation, and suppresses inflammation 
[10].. Targeted inhibition of BET proteins has therefore been shown to be 
protective in several autoimmune disease models [12-15]. 
In 2010 the first two BET inhibitors, JQ1 and I-BET, were reported 
simultaneously from two different groups [15,16]. JQ1 suppresses inflammatory 
responses mediated by Th17 through disruption of BRD4 functioning and its 
downstream signaling cascades [14,17]. However, its systemic toxicity and 
insufficient pharmacokinetic effect in vivo have limited its potential for clinical 
application [18,19]. A new BET inhibitor, OTX015, has been reported to be 
better tolerated in clinical trials for hematologic malignancies and solid tumors 
[20,21]. Given the potential to extend its application to autoimmune conditions, 
we sought to interrogate the effect of OTX015 on the classical proinflammatory 
CD4+ T cell subsets in vitro as the first stage in its pre-clinical evaluation for 
therapeutic application. In this study we show that murine and human subsets 
of CD4+ T cells respond differently to OTX015 and that OTX015 preferentially 
acts on human Th17 cells. 
 
2. MATERIALS AND METHODS 
2.1. Healthy Controls 
CD4+ T cells were obtained from up to 80 ml peripheral blood from healthy 
controls (HCs) following informed consent in accordance with National Health 
Service Research Ethic Committee approved protocols at the University 
Hospitals Bristol Foundation Trust, United Kingdom (04/Q2002/84). Written 
informed consent was obtained from all study participants.  
2.2. Materials  
Both OTX015 and JQ1 (Stratech Scientific, UK) were dissolved in DMSO 
to make a stock solution of 10 mM. Aliquots were kept at -80oC for up to 6 
months and diluted with appropriate culture media for in vitro use. Murine 
antibodies for cell culture (anti-CD3, anti-CD28, anti-IL-4, anti-IFN-) and flow 
cytometry (anti-IL-17, anti-IFN-) were purchased from eBioscience (USA) and 
human antibodies (anti-IL-17, anti-IFN-) were purchased from Biolegend (USA) 
or eBioscience (USA). Sorting antibodies (anti-CD3, anti-CD4, anti-CD44, anti-
CD62L for murine and anti-CD45RA, anti-CD45RO, anti-CCR7, anti-CCR6, 
anti-CCR4, anti-CXCR3 for human) were purchased from Biolegend (USA). 
Recombinant murine IL-6 and IL-12 were purchased from PeproTech (USA) 
and recombinant human TGF- was purchased from R&D systems (USA). 
2.3. Cell Isolation 
CD4+ T cells from HCs were enriched by negative selection using the 
RosetteSep® Human CD4+ T cell Enrichment Cocktail (Stemcell Technologies, 
Canada) according to the manufacturer’s instruction. CD4+ T cells were 
removed from the interface between the plasma and density gradient and 
washed twice with RPMI-1640 containing 10% (v/v) fetal calf serum (FCS) 
(Gibco, USA). The purity of CD4+ T cells achieved was greater than 95%. For 
murine CD4+ T cell isolation, cells from lymph nodes and spleens were isolated 
and processed into single cell suspension. CD4+ T cells were isolated using the 
CD4 (L3T4) Microbeads (Miltenyi Biotec, Germany) according to 
manufacturer’s instruction. The purity of CD4+ T cells achieved was greater 
than 95%.  
2.4. Fluorescence-Activated Cell Sorting (FACS) 
Non-specific murine antibody binding was blocked by incubating cells with 
24G2 supernatant for 10 minutes at 4oC followed by incubation with the 
proliferation tracking dye, CellTraceTM Violet (ThermoFisher Scientific, USA) for 
20 minutes at 37oC. The cell surface expression of CD44 and CD62L was used 
to phenotypically discriminate murine naïve (CD44lowCD62Lhigh) from memory 
(CD44highCD62Llow) cells. Similarly, human CD4+ T cells were stained with 
CellTraceTM Violet, and then either sorted for naïve, memory T cells or Th 
subsets (Supplementary Figure 1) according to the following cell surface 
expression: naïve (CD45RA+CD45RO-CCR7+), central memory 
(CD45RO+CD45RA-CCR7+), effector memory (CD45RO+CD45RA-CCR7-), 
Th1 (CCR6-CXCR3+CCR4-), Th17 (CCR6+CXCR3-CCR4+) or IFN- & IL-17 
double positive cells (CCR6+CXCR3+CCR4-). All FACS was performed using 
either the BD Aria (murine) or the BD Influx Systems (human) (BD Biosciences, 
USA) and routinely > 95% purity was achieved.  
2.5. Flow Cytometry 
As for FACS surface staining, nonspecific antibody binding was blocked 
with 24G2 supernatant followed by incubation with primary antibodies against 
surface markers. Intracellular cytokine analysis was carried out by incubating 
the cells with 20 ng/ml PMA, 1 µM ionomycin and 1 µl/ml Golgistop (BD 
Bioscience, USA) for the last 4 hours of culture. Cells were fixed, permeabilized 
with the Cytofix/perm solution (BD Bioscience, USA) and stained with 
intracellular cytokine antibodies. Cells were washed with PBS containing 2% 
FCS twice. The LIVE/DEADTM fixable dead cell stain kit (Thermofisher Scientific, 
USA) was used to exclude dead cells from analysis. All samples were acquired 
using the BDTM LSR II or BD LSR FortessaTM X-20 (BD Bioscience, USA) and 
data were analyzed with FlowJo v10 (Tree Star Inc, USA). 
2.6. Murine CD4+ T Cell In Vitro Assays 
To measure cell proliferation, isolated CD4+ T cells were stained with 
CellTraceTM Violet and seeded into 96-well plates (0.1 million cells/well) pre-
coated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28. RPMI1640 Culture media 
was supplemented with polarization cytokines and BET inhibitor: Th1 (20 ng/ml 
mIL-12, 100 ng/ml anti-IL-4) and Th17 (20 ng/ml mIL-6, 1 ng/ml TGF-1, 100 
ng/ml anti-IL-4, 100 ng/ml anti-IFN-). All cells were cultured with RPMI-1640 
containing 10% FCS, Pen/Strep and 2-mercaptoethanol in a humidified 
incubator containing 5% CO2 at 37oC. 
2.7. Human CD4+ T Cell In Vitro Assays 
CD4+ T cells or FACS sorted naïve, memory T cells or Th subsets were 
seeded in 96 well microplates (0.1 million cells/well), stimulated with 
DynabeadsTM Human T-Activator CD3/CD28 (Gibco, USA) and BET inhibitor. 
Proliferation and intracellular cytokine expression were assessed on day 5 
following 4 hours of PMA and ionomycin stimulation. All cultures were incubated 
in a humidified incubator containing 5% CO2 at 37oC. 
2.8. Quantitative Real-Time PCR (qPCR)  
Total RNA was extracted using RNeasy Plus Mini Kit and micro Kit (Qiagen, 
Germany) dependent on input cell number. RNA was reverse transcribed using 
GoScript reverse transcriptase (Promega, USA) in ProFlex PCR system 
(Applied Biosystems, USA). qPCR was performed using QuantStudio 3 System 
(Thermofisher Scientific, USA). The following Taqman probes from Applied 
Biosystems were used: Actin-Beta (Hs_0160556_g1), RORC 
(Hs_01076122_m1) and TBX21 (Hs00203436_m1). 
2.9. Statistics 
The statistical analyses were performed with Prism Graphpad 7.0 
(GraphPad Software, USA). Mann-Whitney U test, Kruskal-Wallis test or two-
way ANOVA test were used accordingly.  
 
3. RESULTS 
3.1. OTX015 differentially affects murine naïve and memory CD4+ T cells 
JQ1 has previously been shown to suppress cytokine expression in Th17 
cells [14]. As OTX015 is a new BET inhibitor, we first tested whether OTX015 
could suppress Th1 and Th17 subsets induced from FACS sorted murine naïve 
CD4+ T cells. We polarized these cells into Th1 or Th17 subsets in the presence 
or absence of 50 nM of OTX015 for 72 hours (Figure 1A and 1B), and found 
that in our in vitro system OTX015 had a more profound effect on IFN- from 
induced Th1 than on IL-17 from Th17 cells. The optimal concentration of 
OTX015 and treatment duration were selected according to the cell viability and 
the expression of cytokines from dose-dependent and time-course studies 
(Supplementary Figure 2). At 50 nM, no significant viability change was 
observed between OTX015 treated or untreated control cultures 
(Supplementary Figure 2). However, at higher concentrations, OTX015 was 
more detrimental to the viability of murine than human CD4+ T cells. In addition, 
we confirmed that OTX015 and JQ1 had equivalent inhibitory effects on murine 
CD4+ T cell subsets, as indicated by the cytokine production and cell 
proliferation of Th1 and Th17 subsets after treatment (Supplementary Figure 3). 
These results indicated that OTX015 could efficiently suppress differentiation 
of CD4+ T cells from naïve cells. 
Naïve and memory CD4+ T cells have different roles in the immune system. 
Their epigenetic status and epigenetic alterations toward stimulation are also 
different [22-24]. We therefore investigated the effect of OTX015 on stimulated 
memory CD4+ T cells. Murine CD4+ memory T cells were also sorted by FACS 
and stimulated with anti-CD3/CD28 in the presence or absence of OTX015 for 
24 hours. Strikingly, OTX015 had no effect on the production of IFN- or IL-17 
in murine memory CD4+ T cells (Figure 1C and 1D). These results indicate that 
different subtypes of CD4+ T cells may respond differently to epigenetic 
regulators.  
 
3.2. OTX015 preferentially inhibits IL-17 over IFN- in human CD4+ T cells  
To test the potential to translate our murine findings to human disease, we 
applied OTX015 on human CD4+ T cells for 5 days. OTX015 suppressed, in a 
dose-dependent manner, both human CD4+ T cell proliferation (Figure 2A and 
2B) and the frequency of IFN- single-positive, IL-17 single-positive, and IL-
17/IFN- double-positive subsets in a mixed population of human CD4+ T cells 
(Figure 2C – 2F). Unlike murine CD4+ T cells, the cell viability change was less 
than 10% at the highest dose of OTX015 (Supplementary Figure 4). Between 
the two main proinflammatory cytokines IFN- and IL-17, OTX015 preferentially 
inhibited IL-17. At 312.5 nM, OTX015 restrained more than 50% of IL-17 
expression but failed to significantly suppress IFN-. Next, we next conducted 
a comparison of JQ1 and OTX015, and found that there was no significant 
difference between these two BET inhibitors in either affecting cell proliferation 
or cytokine production (Supplementary Figure 5). These results were different 
from that of murine cells, prompting us to question whether OTX015’s 
differential effect on naïve and memory T cells would be consistent across 
species. 
 
3.3. OTX015 preferentially suppresses IL-17 in human memory CD4+ T 
cells. 
Next, we tested OTX015 on different human CD4+ T cell subpopulations. 
Human naïve and memory CD4+ T cells subsets were isolated by FACS and 
activated in vitro with or without OTX015 for 5 days. As shown in Figure 3A and 
3B, OTX015 dose-dependently suppressed the proliferation of all subsets 
without significantly affecting the cell viability of naïve T cells and memory cells 
at lower doses of OTX015 (Supplementary Figure 6). As for cytokines, IL-17 
was barely detectable in the naïve CD4+ T cells, while IL-17 single-positive cells 
accounted for approximately 3.8% and 5.7% in the effector (TEM) and central 
(TCM) memory T cells, respectively. OTX015 significantly suppressed the 
proliferation and frequency both of IL-17 single-positive and IL-17/IFN- double-
positive in TEM and TCM in a dose-dependent manner (Figure 3C, 3D and 3F). 
However, OTX015 had limited suppressive effects on the production of IFN-γ 
from naïve cells and even caused a slight increase in IFN- production from 
TEM (Figure 3E). Consitent with this, for naïve CD4+ T cells, there was no 
significant change in the level of TBX21 and RORC between OTX015 treated 
and control group. But in TCM, RORC was significantly inhibited by OTX015. 
In TEM cells, we saw an increase in TBX21 and a decrease in RORC by 
OTX015 (Figure 3G). 
 
3.4. OTX015 inhibits Th1, Th17 and IFN- & IL-17 double positive cell 
proliferation but preferentially acts on Th17 cytokines in human Th 
subsets 
To study the effect of OTX015 on human CD4+ T cell subsets in more detail, 
Th1, Th17 and IFN- & IL-17 double positive cells were sorted based on the 
expression of chemokine receptors and activated for 5 days with 2,500 nM 
OTX015. As shown in Figure 4A and 4B, OTX015 significantly suppressed the 
proliferation of all three cell subsets. On day 5, Th1 and IFN- & IL-17 double 
positive cells primarily produced IFN-, while Th17 cells primarily produced IL-
17 (Figure 4C). OTX015 was able to significantly reduce IL-17 production from 
Th17 cells but had limited ability to suppress the production of IFN- from Th1, 
or to suppress either IL-17 or IFN- from IFN- & IL-17 double positive cells 




In this study, we have shown that the BET inhibitor OTX015 significantly 
inhibits CD4+ T cell proliferation and differentially suppressed their expression 
of IL-17 and IFN- across murine and human CD4+ T cell subsets. Our findings 
were confirmed with detailed dose-response and time-course studies in both 
murine and human CD4+ T cells. BET inhibitors have been extensively studied 
in cancer and inflammatory diseases. JQ1 is a thoroughly-researched 
representative BET inhibitor and is reported to selectively block IL-17A and IL-
22 in human naïve CD4+ T cells under Th17 polarizing conditions and to block 
IFN- under Th1 biased conditions [14]. I-BET-762 has been also reported to 
downregulate IL-17 and IFN- in murine T cells [25]. However, JQ1 has a 
relatively short half-life in the plasma: 0.9 hours with intravenous injection of 5 
mg/kg or 1.4 hours with oral administration of 10 mg/kg [26]. Moreover, it has 
been shown to cause severe weight loss and leukopenia in mice [19]. These 
drawbacks limit the clinical application of JQ1. OTX015, as a new BET inhibitor, 
belongs to the azepine chemical family like JQ1. It is the first oral BET inhibitor 
which has been tested in clinical trials in oncology [20, 21, 27]. Our results have 
shown that OTX015 and JQ1 have similar inhibitory effects on the inflammatory 
cytokine production from murine and human CD4+ T cells. Given that OTX015 
is much safer and more stable than JQ1, OTX015 therefore has the potential 
to also be developed for the treatment of autoimmune diseases. 
Downregulation of IFN- in Th1 and IL-17 in Th17 cells is a hallmark of 
inflammatory suppression. Th17 cells secreting IFN- are considered more 
pathogenic and are more resistant to corticosteroid suppression [28]. Our 
results revealed that OTX015 reduced the frequencies of IFN- and IL-17 
single-positive and IFN-/IL-17 double-positive populations in whole human 
CD4+ T cells, which indicates a protective role of OTX015 in the inflammatory 
context. But it remains a caveat that OTX015 did not significantly suppress IFN-
 & IL-17 double positive cells in polarized Th17 cultures. However, given that 
it is well-established that both the activation and proliferation of T cells have 
important roles in the pathogenesis of autoimmune disorders. Our data suggest 
that the anti-proliferative effect of OTX015 may work synergistically with its anti-
inflammatory effect to treat autoimmune diseases. 
Although naïve and memory CD4+ T cells have over 95% similarity in 
global gene expression, they display different expression patterns of immune-
related genes, which reflects the difference in epigenetic status of these two 
subsets [22]. In support of this notion, previous studies showed that T cells 
exhibited epigenetic remodeling between initial stimulation and subsequent re-
stimulation [23, 24]. Our results demonstrate that naïve and memory T cells 
respond differently to the epigenetic “reader” inhibition. OTX015 could 
efficiently suppress IFN- in induced murine Th1 cells, but not spontaneously 
secreted IFN- from murine memory T cells. The results were replicated using 
human total and memory T cells. Our results therefore hint that the epigenetic 
context must be considered when applying BET targeting compounds. It is also 
interesting that IL-17 but not IFN- was suppressed in human memory CD4+ T 
cells. This may be therapeutically desirable in the context of chronic 
inflammation as persistent IFN- expression has potential benefit in the late 
stages of conditions such as autoimmune uveitis [29]. 
Our results showed that both Th cell proliferation and cytokine production 
were suppressed by OTX015. To exclude a general suppressive effect, we 
performed qPCR to quantify the mRNA expression of critical transcription 
factors in human CD4+ T cell subsets. RORC but not TBX21 was suppressed 
in human central memory T cells by OTX015. In TEM, we even saw an elevated 
expression of TBX21, which is different from that in naïve CD4+ T cell subsets. 
These results echo the protein changes reported for JQ1, in which there was 
reduction of RORC and RORA, but not TBX21, GATA3 or FOXP3 in 
corresponding CD4+ T cell subtypes [14].  
 
CONCLUSION 
In summary, we have shown that the BET inhibitor OTX015 can efficiently 
suppress the proliferation of murine and human Th cells as well as subset-
specific production of their pro-inflammatory cytokines. In addition, we have 
also demonstrated that both murine and human naïve CD4+ T cells reacted 
differently to OTX015 when compared to murine and human memory CD4+ T 
cells. These results indicate the potential benefits and also immune context-




PTM = post-translational modifications 
BET = Bromodomain extra-terminal protein 
TCM = central memory T cells 
TEM = effector memory T cells 
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Figure 1. Effects of OTX015 on murine naïve and memory CD4+ T cells. 
Murine CD4+ T cells were treated with or without 50 nM OTX015 for 72 hours 
(naïve T cells) or 24 hours (memory T cells). (A) Representative dot plots of 
IFN- and IL-17 in induced Th1 and Th17 from murine naïve CD4+ T cells. (B) 
Frequency of IFN-−expressing Th1 or IL-17−expressing Th17 induced from 
murine naïve CD4+ T cell (n = 5). (C) Representative dot plots of IFN- and IL-
17 in stimulated memory CD4+ T cells. (D) Frequency of IFN-− or IL-17− 
expressing cells in the stimulated memory CD4+ T cell population (n = 4). Data 
are shown as means ± SD, **** P < 0.001. 
 
Figure 2. Effects of OTX015 on human CD4+ T cells.  
Human CD4+ T cells were isolated and stimulated with anti-CD3/CD28 for 5 
days in the presence of escalating concentrations of OTX015 on day 5. (A) 
Representative histograms showing the proliferation of stimulated human CD4+ 
T cells. (B) Suppression of proliferation of the stimulated human CD4+ T cells 
(n=12). (C) Representative dot plots of IL-17− and IFN-− expressing cells in 
stimulated human CD4+ T cells. (D-F) Frequency of IL-17 (D), IFN- (E) and IL-
17 (F), IFN-g double positive in human whole CD4+ T cells treated with different 
concentration of OTX015 (n=12). Data are shown as means ± SD, ** P < 0.01 
*** P < 0.005 **** P < 0.001.     
 
Figure 3. Effects of OTX015 on human naïve and memory CD4+ T cells. 
Isolated human CD4+ T cells were sorted into naïve or memory subsets. The 
memory subsets were stimulated with anti-CD3/CD28 for 5 days. Cells were 
treated with or without varying doses of OTX015 on day 5. (A) Representative 
histograms showing the proliferation of different human CD4+ T cell subsets. (B) 
Representative dot plots of IL-17− and IFN-−expressing cells in different 
human CD4+ T cell subsets. (C) Suppression of proliferation of different human 
CD4+ T cell subsets (n ≥ 4). (D-F) Frequencies of IL-17− (D) and IFN-
− ()expressing or double positive (F) cells in different human CD4+ T cell 
subsets (n ≥ 4). (G) The mRNA levels of transcription factors in different human 
CD4+ T cell subsets (n=4). Data are shown as means ± SD, * P < 0.05 ** P < 
0.01 *** P < 0.005 **** P < 0.001. TCM: central memory T cells; TEM: effector 
memory T cells.               
 
Figure 4. Effects of OTX015 on human Th1, Th17 and IFN- & IL-17 double 
positive cells subsets. 
Human Th1, Th17 and IFN- & IL-17 double positive (DP) cells subsets were 
sorted by corresponding chemokine receptors and treated with 2,500 nM 
OTX015 for 5 days. (A) Representative histograms showing the proliferation 
of different human T cell subsets. (B) Suppression of proliferation of different 
human T cell subsets (n=6 for Th1 and n=7 for Th17/DP cells). (C) 
Representative dot plots of IL-17- and IFN-−expressing cells in different 
human T cell subsets. (D-G) Frequencies of IL-17- and IFN-−expressing cells 
in different human T cell subsets (n=6 for Th1 and n=7 for Th17/DP cells). 
Data are shown as means ± SD, ** P < 0.01. DP cells = IFN- & IL-17 double 
positive cells. 
